The Final Word: Navigating Pharma's Powerhouse and Gold's Gleam in Today's Markets

Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Weight-Loss Drug Wars: Novo Nordisk Eyes Vials for Wegovy in High-Stakes Battle

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

Eli Lilly's Ascendant Journey: Why Its Premium Price Tag Might Just Be Worth It

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Eli Lilly CEO Sees Medicare Support as Game-Changer for New Oral Obesity Pill

The Eli Lilly Phenomenon: Unpacking the Rocket Fuel Behind the Stock's Astounding Climb

Unpacking GLP-1 Drugs: A Human's Guide to the Latest Metabolic Marvels

A Glimmer of Hope for Achy Joints: Could Weight-Loss Drugs Be Our Next Weapon Against Arthritis?

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

Eli Lilly Slashes Zepbound Prices Amid Political Pressure and Trump's Claims

The Next Frontier: Unpacking 'Ozempic 2.0' and the Future of Weight Management

The Dawn of a New Era in Weight Loss Medicine

The Curious Case of Microdosing Obesity Drugs: A New Trend or a Risky Gamble?

The Trillion-Dollar Bet: How Eli Lilly is Reshaping the Global Economy

Eli Lilly's Trillion-Dollar Triumph: A New Chapter in Pharmaceutical History

The Pharma Giants' Bold Leap: Novo Nordisk and Eli Lilly Eyeing Direct Sales of Obesity Drugs to Employers

Wegovy's Reckoning: Novo Nordisk's CEO Digs In as the Weight Loss Market Heats Up

The Lilly Lull: Why a Minor Dip Might Be Just a Blip in a Pharmaceutical Powerhouse's Journey

The Price of Progress? Unpacking the Billion-Dollar Buzz Around America's New Weight-Loss Fixes

The GLP-1 Gambit: Pharma Giants, Trump, and the High Stakes of Drug Prices

The Great Negotiation: Big Pharma, Weight Loss, and the White House

A Major Turnaround: US Obesity Rates Witness Significant Decline in 2024

A Healthier Horizon: US Obesity Rates Show Promising Decline in 2024

The Future of Fat Loss: Novo Nordisk Unleashes Its Next-Gen Weapon in the High-Stakes Drug Wars

The Mind Behind Miracles: Daniel Skovronsky's Blueprint for Eli Lilly's R&D Revolution

The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition

The Weight Loss Revolution: Drugs vs. Surgery – Which Path is Right for You?

Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s

Beyond Blood Sugar: Ozempic and Zepbound's Unexpected Promise in Psoriasis Treatment

The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging

FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video

The Next Frontier: Eli Lilly and Novo Nordisk Gear Up for a Revolution in Oral Obesity Treatment

The Ozempic Effect: How Weight-Loss Drugs Are Reshaping Economies and Creating Thousands of Jobs

The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker